Nine cases of Dilantin-induced focal cerebral atrophy have been reported to the U.S. Food and Drug Administration (FDA).
Those who suffered from Dilantin-induced focal cerebral atrophy were among a total of 11,836 Dilantin adverse event reports.
According to FactMed, which assesses the risks of more than 20,000 different medications, the FDA typically only receives adverse reports of critical and severe cases so the number of Dilantin complications may actually be even higher.
The FDA reports that the average percentage of any medication causing cerebellar atrophy as a side effect is 0.0023%, while the number of Dilantin cerebellar atrophy as a reported side effect is higher at 0.0760%.
What is Dilantin Focal Cerebral Atrophy?
The cerebellum portion of the brain is what controls body movements such as speech, posture, balance and coordination. It is responsible for allowing the human body to have precise and balanced motion.
When cerebellar atrophy (or focal cerebral atrophy) occurs, brain tissue cells have lost neurons and the connections between them. When this takes place, individuals can experience a lack of balance, which makes even basic tasks like walking difficult.
Often, cerebellar atrophy symptoms are described as “stroke-like” and include the following:
- Unsteady, lurching walk, which often includes a back and forth tremor in the main part of the body
- Slow speech
- Slurred speech
- Nystagmus (small, rapid movements in the eyes)
- Slow, unsteady, jerky movements in the arms or legs
Physicians who have treated cases of Dilantin induced focal cerebral atrophy report that symptoms can be treated once a patient stops taking the medication. However, occasionally focal cerebral atrophy leaves patients with permanent injuries, especially when it comes to muscle coordination.
Dilantin Cerebellar Atrophy Study
In a Dilantin study published in Seizure: European Journal of Epilepsy, researchers compared the MRIs of 100 patients who had been taking Dilantin (phenytoin) for at least two months.
Researchers noted that focal cerebral atrophy was detected in 35 percent of patients. After analyzing all the variables including gender, duration of epilepsy, age and length of use of Dilantin, the study was conclusive in determining that cerebellar atrophy is associated with long-term use of the medication.
In their conclusion, researchers state: “Although duration of epilepsy may have an influence in the CA, this is clearly less important than the time of exposure to phenytoin.”
Dilantin Lawsuit Information
Dilantin is manufactured by Pfizer for the prevention and management of seizures. The anti-seizure medication effectively slows down brain impulses. Although it is primarily used to treat epilepsy, it is also occasionally used as a seizure preventative for patients who have suffered a head injury.
As shown in the Dilantin study, extensive or long-term exposure of phenytoin can lead to focal cerebral atrophy.
Dilantin focal cerebral atrophy attorneys are currently investigating the link between Dilantin and cerebellar degeneration. If you took Dilantin (phenytoin) and were diagnosed with focal cerebral atrophy, you could be eligible to file a Dilantin cerebellar atrophy lawsuit.
In general, phenytoin lawsuits are filed individually by each plaintiff and are not class actions.
Do YOU have a legal claim? Fill out the form on this page now for a free, immediate, and confidential case evaluation. The attorneys who work with Top Class Actions will contact you if you qualify to let you know if an individual Dilantin lawsuit or Dilantin class action lawsuit is best for you. Hurry — statutes of limitations may apply.
Top Class Actions is a Proud Member of the American Bar Association
LEGAL INFORMATION IS NOT LEGAL ADVICE
Top Class Actions Legal Statement
©2008 – 2016 Top Class Actions® LLC
Various Trademarks held by their respective owners
Get Help – It’s Free
Join a Free Dilantin, Phenytoin Cerebral Atrophy Class Action Lawsuit Investigation
If you or a loved one were injured by Dilantin/phenytoin side effects, you may have a legal claim. Fill out the form for a free case evaluation.
An attorney will contact you if you qualify to discuss the details of your potential case.
- First Name*
- Last Name*
- Street Address*
- Apt. #
- City*
- State*
AlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareDistrict of ColumbiaFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWest VirginiaWisconsinWyomingArmed Forces AmericasArmed Forces EuropeArmed Forces Pacific
- Zip Code*
- Phone*
- Email*
- Please list an emergency contact's name and phone number:*
- What is the best time to call you?*
- Please select the drug you/your loved on took:*
-
Phenytoin
-
Dilantin
-
Other (please describe in the Additional Details box below)
-
- What year(s) did you/your loved one take this drug?*
- Which of the following were you/your loved one medically diagnosed with?*
-
Cerebellar atrophy
-
No medical diagnosis
-
Other (please describe in the Additional Details box below)
-
- Please enter any additional details you would like the staff reviewing your submission to know.*
- Have you already retained an attorney to file a phenytoin lawsuit?*
- I understand and agree that submitting this form does not create an attorney-client relationship and that the information I submit is not confidential or privileged and may be shared.*
-
Yes
-
- ¿Necesita un orador español?
- Yes
- No
-
if(typeof gf_global == ‘undefined’) var gf_global = {“gf_currency_config”:{“name”:”U.S. Dollar”,”symbol_left”:”$”,”symbol_right”:””,”symbol_padding”:””,”thousand_separator”:”,”,”decimal_separator”:”.”,”decimals”:2},”base_url”:”http:\/\/topclassactions.com\/wp-content\/plugins\/gravityforms”,”number_formats”:[],”spinnerUrl”:”http:\/\/topclassactions.com\/wp-content\/plugins\/gravityforms\/images\/spinner.gif”};jQuery(document).bind(‘gform_post_render’, function(event, formId, currentPage){if(formId == 162) {gformInitChosenFields(‘#input_162_5′,’No results matched’);if(!/(android)/i.test(navigator.userAgent)){jQuery(‘#input_162_7’).mask(‘(999) 999-9999’).bind(‘keypress’, function(e){if(e.which == 13){jQuery(this).blur();} } );}} } );jQuery(document).bind(‘gform_post_conditional_logic’, function(event, formId, fields, isInit){gformInitChosenFields(‘#input_162_5′,’No results matched’);} ); jQuery(document).ready(function(){jQuery(document).trigger(‘gform_post_render’, [162, 1]) } );
The post FDA Reports Nine Cases of Dilantin Focal Cerebral Atrophy appeared first on Top Class Actions.
No comments:
Post a Comment